Anti‐Ri

An antibody associated with paraneoplastic opsoclonus and breast cancer

F. Antonio Luque, Henry M. Furneaux, Reuven Ferziger, Marc K. Rosenblum, Shirley H. Wray, S. Clifford Schold, Michael J. Glantz, Kurt Jaeckle, Haim Biran, Martin Lesser, William A. Paulsen, Mary E. River, Jerome B. Posner

Research output: Contribution to journalArticle

317 Citations (Scopus)

Abstract

The serum and cerebrospinal fluid (CSF) of 8 women with ataxia, 6 of whom also had eye movement abnormalities believed to be opsoclonus, were found to contain a highly specific antineuronal antibody we call anti‐Ri. Seven of the 8 women also had or developed cancer: carcinoma of the breast in 5, adenocarcinoma in an axillary lymph node in 1, and carcinoma of the fallopian tube in 1. Four patients presented with the neurological disorder; the cancer was diagnosed first in the other 4. Immunohistochemical studies using serum or CSF from all 8 patients revealed a highly specific antibody interaction with central nervous system neuronal nuclei but not with glial or other cells; the titer ranged from 1:5,000 to 1:320,000 in serum and from 1:2,000 to 1:16,000 in CSF. Biotinylated IgG from the patients' serum reacted with the tumors of 3 of 4 patients with anti‐Ri antibody but not with breast cancers from patients without anti‐Ri antibody. Immunoblots against cerebral cortex neuronal extracts identified protein antigens of 55‐kd and 80‐kd relative molecular mass. Serum titers by immunoblot ranged from 1:500 to more than 1:40,000 and CSF titers, from 1:10 to 1:2,000. The relative amount of anti‐Ri was always higher in CSF than in serum. The antibody was not present in sera from normal individuals; patients with breast cancer without opsoclonus; other patients with opsoclonus; or patients with other paraneoplastic syndromes related to breast, ovarian, or small‐cell lung cancer. We conclude that the presence of anti‐Ri antibody identifies a subset of patients with paraneoplastic ataxia and eye movement disorders (opsoclonus) who usually suffer from breast or other gynecological cancer; the antibody when present is a useful marker for an underlying malignancy.

Original languageEnglish (US)
Pages (from-to)241-251
Number of pages11
JournalAnnals of Neurology
Volume29
Issue number3
DOIs
StatePublished - Jan 1 1991

Fingerprint

Ocular Motility Disorders
Breast Neoplasms
Antibodies
Cerebrospinal Fluid
Serum
Ataxia
Neoplasms
Breast
Eye Abnormalities
Carcinoma
Paraneoplastic Syndromes
Fallopian Tubes
Eye Movements
Nervous System Diseases
Neuroglia
Cerebral Cortex
Lung Neoplasms
Adenocarcinoma
Central Nervous System
Immunoglobulin G

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

Luque, F. A., Furneaux, H. M., Ferziger, R., Rosenblum, M. K., Wray, S. H., Schold, S. C., ... Posner, J. B. (1991). Anti‐Ri: An antibody associated with paraneoplastic opsoclonus and breast cancer. Annals of Neurology, 29(3), 241-251. https://doi.org/10.1002/ana.410290303
Luque, F. Antonio ; Furneaux, Henry M. ; Ferziger, Reuven ; Rosenblum, Marc K. ; Wray, Shirley H. ; Schold, S. Clifford ; Glantz, Michael J. ; Jaeckle, Kurt ; Biran, Haim ; Lesser, Martin ; Paulsen, William A. ; River, Mary E. ; Posner, Jerome B. / Anti‐Ri : An antibody associated with paraneoplastic opsoclonus and breast cancer. In: Annals of Neurology. 1991 ; Vol. 29, No. 3. pp. 241-251.
@article{b0c7130119cd4deda30af2a870b9961d,
title = "Anti‐Ri: An antibody associated with paraneoplastic opsoclonus and breast cancer",
abstract = "The serum and cerebrospinal fluid (CSF) of 8 women with ataxia, 6 of whom also had eye movement abnormalities believed to be opsoclonus, were found to contain a highly specific antineuronal antibody we call anti‐Ri. Seven of the 8 women also had or developed cancer: carcinoma of the breast in 5, adenocarcinoma in an axillary lymph node in 1, and carcinoma of the fallopian tube in 1. Four patients presented with the neurological disorder; the cancer was diagnosed first in the other 4. Immunohistochemical studies using serum or CSF from all 8 patients revealed a highly specific antibody interaction with central nervous system neuronal nuclei but not with glial or other cells; the titer ranged from 1:5,000 to 1:320,000 in serum and from 1:2,000 to 1:16,000 in CSF. Biotinylated IgG from the patients' serum reacted with the tumors of 3 of 4 patients with anti‐Ri antibody but not with breast cancers from patients without anti‐Ri antibody. Immunoblots against cerebral cortex neuronal extracts identified protein antigens of 55‐kd and 80‐kd relative molecular mass. Serum titers by immunoblot ranged from 1:500 to more than 1:40,000 and CSF titers, from 1:10 to 1:2,000. The relative amount of anti‐Ri was always higher in CSF than in serum. The antibody was not present in sera from normal individuals; patients with breast cancer without opsoclonus; other patients with opsoclonus; or patients with other paraneoplastic syndromes related to breast, ovarian, or small‐cell lung cancer. We conclude that the presence of anti‐Ri antibody identifies a subset of patients with paraneoplastic ataxia and eye movement disorders (opsoclonus) who usually suffer from breast or other gynecological cancer; the antibody when present is a useful marker for an underlying malignancy.",
author = "Luque, {F. Antonio} and Furneaux, {Henry M.} and Reuven Ferziger and Rosenblum, {Marc K.} and Wray, {Shirley H.} and Schold, {S. Clifford} and Glantz, {Michael J.} and Kurt Jaeckle and Haim Biran and Martin Lesser and Paulsen, {William A.} and River, {Mary E.} and Posner, {Jerome B.}",
year = "1991",
month = "1",
day = "1",
doi = "10.1002/ana.410290303",
language = "English (US)",
volume = "29",
pages = "241--251",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

Luque, FA, Furneaux, HM, Ferziger, R, Rosenblum, MK, Wray, SH, Schold, SC, Glantz, MJ, Jaeckle, K, Biran, H, Lesser, M, Paulsen, WA, River, ME & Posner, JB 1991, 'Anti‐Ri: An antibody associated with paraneoplastic opsoclonus and breast cancer', Annals of Neurology, vol. 29, no. 3, pp. 241-251. https://doi.org/10.1002/ana.410290303

Anti‐Ri : An antibody associated with paraneoplastic opsoclonus and breast cancer. / Luque, F. Antonio; Furneaux, Henry M.; Ferziger, Reuven; Rosenblum, Marc K.; Wray, Shirley H.; Schold, S. Clifford; Glantz, Michael J.; Jaeckle, Kurt; Biran, Haim; Lesser, Martin; Paulsen, William A.; River, Mary E.; Posner, Jerome B.

In: Annals of Neurology, Vol. 29, No. 3, 01.01.1991, p. 241-251.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anti‐Ri

T2 - An antibody associated with paraneoplastic opsoclonus and breast cancer

AU - Luque, F. Antonio

AU - Furneaux, Henry M.

AU - Ferziger, Reuven

AU - Rosenblum, Marc K.

AU - Wray, Shirley H.

AU - Schold, S. Clifford

AU - Glantz, Michael J.

AU - Jaeckle, Kurt

AU - Biran, Haim

AU - Lesser, Martin

AU - Paulsen, William A.

AU - River, Mary E.

AU - Posner, Jerome B.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - The serum and cerebrospinal fluid (CSF) of 8 women with ataxia, 6 of whom also had eye movement abnormalities believed to be opsoclonus, were found to contain a highly specific antineuronal antibody we call anti‐Ri. Seven of the 8 women also had or developed cancer: carcinoma of the breast in 5, adenocarcinoma in an axillary lymph node in 1, and carcinoma of the fallopian tube in 1. Four patients presented with the neurological disorder; the cancer was diagnosed first in the other 4. Immunohistochemical studies using serum or CSF from all 8 patients revealed a highly specific antibody interaction with central nervous system neuronal nuclei but not with glial or other cells; the titer ranged from 1:5,000 to 1:320,000 in serum and from 1:2,000 to 1:16,000 in CSF. Biotinylated IgG from the patients' serum reacted with the tumors of 3 of 4 patients with anti‐Ri antibody but not with breast cancers from patients without anti‐Ri antibody. Immunoblots against cerebral cortex neuronal extracts identified protein antigens of 55‐kd and 80‐kd relative molecular mass. Serum titers by immunoblot ranged from 1:500 to more than 1:40,000 and CSF titers, from 1:10 to 1:2,000. The relative amount of anti‐Ri was always higher in CSF than in serum. The antibody was not present in sera from normal individuals; patients with breast cancer without opsoclonus; other patients with opsoclonus; or patients with other paraneoplastic syndromes related to breast, ovarian, or small‐cell lung cancer. We conclude that the presence of anti‐Ri antibody identifies a subset of patients with paraneoplastic ataxia and eye movement disorders (opsoclonus) who usually suffer from breast or other gynecological cancer; the antibody when present is a useful marker for an underlying malignancy.

AB - The serum and cerebrospinal fluid (CSF) of 8 women with ataxia, 6 of whom also had eye movement abnormalities believed to be opsoclonus, were found to contain a highly specific antineuronal antibody we call anti‐Ri. Seven of the 8 women also had or developed cancer: carcinoma of the breast in 5, adenocarcinoma in an axillary lymph node in 1, and carcinoma of the fallopian tube in 1. Four patients presented with the neurological disorder; the cancer was diagnosed first in the other 4. Immunohistochemical studies using serum or CSF from all 8 patients revealed a highly specific antibody interaction with central nervous system neuronal nuclei but not with glial or other cells; the titer ranged from 1:5,000 to 1:320,000 in serum and from 1:2,000 to 1:16,000 in CSF. Biotinylated IgG from the patients' serum reacted with the tumors of 3 of 4 patients with anti‐Ri antibody but not with breast cancers from patients without anti‐Ri antibody. Immunoblots against cerebral cortex neuronal extracts identified protein antigens of 55‐kd and 80‐kd relative molecular mass. Serum titers by immunoblot ranged from 1:500 to more than 1:40,000 and CSF titers, from 1:10 to 1:2,000. The relative amount of anti‐Ri was always higher in CSF than in serum. The antibody was not present in sera from normal individuals; patients with breast cancer without opsoclonus; other patients with opsoclonus; or patients with other paraneoplastic syndromes related to breast, ovarian, or small‐cell lung cancer. We conclude that the presence of anti‐Ri antibody identifies a subset of patients with paraneoplastic ataxia and eye movement disorders (opsoclonus) who usually suffer from breast or other gynecological cancer; the antibody when present is a useful marker for an underlying malignancy.

UR - http://www.scopus.com/inward/record.url?scp=0026071720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026071720&partnerID=8YFLogxK

U2 - 10.1002/ana.410290303

DO - 10.1002/ana.410290303

M3 - Article

VL - 29

SP - 241

EP - 251

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 3

ER -

Luque FA, Furneaux HM, Ferziger R, Rosenblum MK, Wray SH, Schold SC et al. Anti‐Ri: An antibody associated with paraneoplastic opsoclonus and breast cancer. Annals of Neurology. 1991 Jan 1;29(3):241-251. https://doi.org/10.1002/ana.410290303